文章摘要
王镜森,郑智方,屈小莹,杜 楠,张尊胜.帕金森病患者血清klk6、HSP70检测的临床意义研究[J].,2023,(19):3744-3748
帕金森病患者血清klk6、HSP70检测的临床意义研究
Study of Clinical Significance of Serum Klk6 and HSP70 Detection in Patients with Parkinson's Disease
投稿时间:2023-05-25  修订日期:2023-06-21
DOI:10.13241/j.cnki.pmb.2023.19.029
中文关键词: 帕金森病  klk6  HSP70  病情严重程度  认知障碍
英文关键词: Parkinson's disease  klk6  HSP70  Severity of condition  Cognitive impairment
基金项目:江苏省"六大人才高峰"资助项目(2015-WSN-064)
作者单位E-mail
王镜森 徐州医科大学研究生院 江苏 徐州 221002 m19552151251@163.com 
郑智方 徐州医科大学研究生院 江苏 徐州 221002  
屈小莹 徐州医科大学研究生院 江苏 徐州 221002  
杜 楠 徐州医科大学研究生院 江苏 徐州 221002  
张尊胜 徐州医科大学附属医院神经内科 江苏 徐州 221002  
摘要点击次数: 226
全文下载次数: 168
中文摘要:
      摘要 目的:探讨帕金森病(PD)患者血清激肽释放酶6(klk6)、热休克蛋白70(HSP70)水平与病情严重程度以及PD轻度认知障碍(PD-MCI)的关系。方法:选择2021年2月至2022年2月徐州医科大学附属医院收治的165例PD患者(PD组),根据修订的Hoehn-Yahr分级将PD患者分为早期组(1.0~2.5级,59例)、中期组(3.0级,65例)和晚期组(4.0~5.0 级,41例),根据是否存在PD-MCI将PD患者分为PD-MCI组(66例)和非PD-MCI组(99例),另选择同期72例于我院门诊体检的健康志愿者为对照组。检测血清klk6、HSP70水平,比较不同分组血清klk6、HSP70水平差异,多因素Logistic回归分析影响PD患者发生PD-MCI的因素。结果:PD组血清klk6水平高于对照组(P<0.05),HSP70水平低于对照组(P<0.05),晚期组血清klk6水平高于早期组和中期组,且中期组血清klk6水平均高于早期组(P<0.05),晚期组血清HSP70水平低于早期组和中期组,且中期组血清HSP70水平低于早期组(P<0.05);PD-MCI组血清klk6水平高于非PD-MCI组(P<0.05),HSP70水平低于非PD-MCI组(P<0.05)。多因素Logistic回归分析结果显示年龄偏高、修订的Hoehn-Yahr分级晚期、高水平klk6是PD患者发生PD-MCI的危险因素(P<0.05),高水平HSP70是PD患者发生PD-MCI的保护因素(P<0.05)。结论:PD患者血清klk6水平增高,HSP70水平降低与修订的Hoehn- Yahr分级增加以及PD-MCI有关,检测血清klk6、HSP70水平有助于评估PD病情以及PD-MCI风险。
英文摘要:
      ABSTRACT Objective: To explore the relationship between serum levels of kallikrein 6 (klk6) and heat shock protein 70 (HSP70) in patients with Parkinson's disease (PD) and the severity of the condition, as well as mild cognitive impairment in PD (PD-MCI). Methods: 165 patients with PD (PD group) who were admitted to Affiliated Hospital of Xuzhou Medical University from February 2021 to February 2022 were selected, the patients with PD were divided into early stage group (stage 1.0 to 2.5, 59 cases), mid stage group (stage 3.0, 65 cases) and late stage group (stage 4.0 to 5.0, 41 cases) according to the revised Hoehn-Yahr stage, the patients with PD were divided into PD-MCI group (66 cases) and non PD-MCI group (99 cases) based on the presence or absence of PD-MCI, and another 72 healthy volunteers who underwent physical examinations in our outpatient department during the same period were selected as control group. The serum levels of klk6 and HSP70 were detected, the differences of serum levels of klk6 and HSP70 among different groups were compared, and the factors affected the occurrence of PD-MCI in patients with PD was analysed by multivariate Logistic regression. Results: Serum klk6 level in PD group was higher than that in control group(P<0.05), serum HSP70 level was lower than that in control group (P<0.05), serum klk6 level in late stage group was higher than that in early and mid stage groups, and serum klk6 level in mid stage group was higher than that in early stage group(P<0.05), serum HSP70 level in late stage group was lower than that in early and mid stage groups. The serum HSP70 level in the mid stage group was lower than that in the early stage group(P<0.05). The serum klk6 level in PD-MCI group was higher than that in non-PD-MCI group (P<0.05), and the serum HSP70 level in PD-MCI group was lower than that in non-PD-MCI group (P<0.05). Multivariate Logistic regression analysis showed that older age, late modified Hoehn-Yahr grade and high level of klk6 were risk factors for PD-MCI in PD patients (P<0.05), and high level of HSP70 was protective factor for PD-MCI in PD patients (P<0.05). Conclusion: The increase of serum klk6 level and the decrease of HSP70 level in PD patients are related to the increase of modified Hoehn-Yahr grade and PD-MCI. The detection of serum klk6 and HSP70 levels is helpful to evaluate the disease condition of PD and the risk of PD-MCI.
查看全文   查看/发表评论  下载PDF阅读器
关闭